Skip to content

Author

K. Jethwa

We have 3 of 177 papers

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Review Aug 2026

Executive Summary of the American Radium Society Appropriate Use Criteria for a Multidisciplinary Treatment Approach to the Management of Resectable Esophageal and Gastroesophageal Junction Adenocarcinoma.

INTRODUCTION In this systematic review and associated guidelines, the American Radium SocietyTM (ARS) thoracic and gastrointestinal oncology expert panels worked together to thoroughly evaluate current literature and provide treatment recommendations for best outcomes for resectable esophagus or gastroesophageal juncti...

C. Anker, Aditya Juloori, D. C. Codipilly et al. · 0 citations
Review Open access Aug 2026

Executive Summary of the American Radium Society (ARS) Appropriate Use Criteria (AUC) for Adjuvant Therapy for Resected Adenocarcinoma of the Pancreas.

This systematic review and guidelines provide up-to-date recommendations focusing on recent advancements for adjuvant treatment of resected PDAC using modern systemic therapy regimens and selective use of radiotherapy using modern techniques.

K. Jethwa, N. Newman, J. Selfridge et al. · 0 citations
Open access Aug 2026

Phase 2 study of futibatinib in combination with pembrolizumab in patients with FGF19 expressing advanced hepatocellular carcinoma

Futibatinib plus pembrolizumab demonstrated an acceptable safety profile but did not meet efficacy thresholds supporting further study in FGF19-expressing HCC, an unmet need after first-line immunotherapy.

Nguyen H. Tran, M. Palmer, Angela Ulrich et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.